ADRB3 and obesity due to melanocortin 4 receptor deficiency: Because of its demonstrated functions in lipid metabolism and observed gene expression dysregulation in obesity, ADRB3 could be reasonably expected to constitute a potential pharmacologic target for obesity treatment.